Lazard Asset Management
SIOX

Lazard Asset Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Lazard Asset Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,741
Closed -$1.32M – 1162
2015
Q3 		$1.32M Sell
12,741
-259
-2% -$30.4K ﹤0.01% 627
2015
Q2 		$2.12M Buy
+13,000
New +$2.2M ﹤0.01% 630

Other funds holding SIOX

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Lazard Asset Management's SIOX Position: Q4 2015 in Review

Lazard Asset Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2015, closing a stake of 12,741 shares — an estimated $1.32M sold.

Lazard Asset Management first reported a position in SIOX in Q2 2015 and held it in 2 quarters. The position peaked at $2.12M in Q2 2015. 70 funds tracked by Wall St. Rank hold SIOX as of Q4 2015.

  • Lazard Asset Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Lazard Asset Management sold 12,741 Sio Gene Therapies Inc. Common Stock shares in Q4 2015, an estimated $1.32M.
  • Lazard Asset Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 2 quarters.
  • Lazard Asset Management's Sio Gene Therapies Inc. Common Stock position peaked at $2.12M in Q2 2015.
  • 70 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2015.

Based on Lazard Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.